Singapore markets closed

Roche Holding AG (RHHVF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
302.77+1.43 (+0.48%)
At close: 03:32PM EST
Full screen
Trade prices are not sourced from all markets
Previous close301.33
Open302.00
Bid0.00 x 0
Ask0.00 x 0
Day's range302.00 - 306.83
52-week range298.00 - 430.00
Volume23,200
Avg. volume6,596
Market cap245.728B
Beta (5Y monthly)0.21
PE ratio (TTM)16.14
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield9.97 (3.24%)
Ex-dividend date17 Mar 2022
1y target estN/A
  • Zacks

    Roche's (RHHBY) 2022 Core Earnings Grow, 2023 Outlook Dismal

    Roche's (RHHBY) performance in 2022 was sub-par as demand for COVID-19-related products declined significantly and 2023 will also be impacted.

  • Reuters

    Roche warns 2023 profits will fall on $5 billion COVID sales hit

    Roche warned on Thursday profits will decline in 2023 as falling demand for its COVID-19 therapy and diagnostics kits will knock sales by over $5 billion, the latest sign that the pharmaceutical industry's years-long pandemic boost is ebbing. Sales and core earnings per share were expected to decrease at a "low single-digit" percentage this year, the Swiss pharmaceuticals and diagnostics company said in a statement. COVID-related sales, mainly from lab testing and antibody treatment Ronapreve, are seen falling by 5 billion Swiss francs ($5.5 billion) for the full year, it said.

  • Zacks

    Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal

    Roche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating early-stage hepatocellular carcinoma, meets its primary endpoint.